These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 2308967)

  • 1. A review of clinical studies evaluating the efficacy of HIV inactivation methods.
    Lawrence DN
    Prog Clin Biol Res; 1990; 324():151-60. PubMed ID: 2308967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for prevalent and incident HIV infection in a cohort of volunteer blood donors in Harare, Zimbabwe: implications for blood safety.
    McFarland W; Mvere D; Katzenstein D
    AIDS; 1997 Sep; 11 Suppl 1():S97-102. PubMed ID: 9376107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light.
    Ben-Hur E; Chan WS; Yim Z; Zuk MM; Dayal V; Roth N; Heldman E; Lazo A; Valeri CR; Horowitz B
    Dev Biol (Basel); 2000; 102():149-55. PubMed ID: 10794102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-antibody seroconversions in Dutch haemophiliacs using heat-treated and non heat-treated coagulation factor concentrates.
    Wolfs TF; Breederveld C; Krone WJ; vd Hoek L; Bakker M; Smit L; Goudsmit J
    Thromb Haemost; 1988 Jun; 59(3):396-9. PubMed ID: 3142077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safer plasma supply from remunerated donors--"The Immuno/Community Bio-Resources experiment".
    Waytes AT; Igel H; Zerlauth G; Wappler N; Lee M; Schwarz O
    Dev Biol (Basel); 2000; 102():37-51. PubMed ID: 10794089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
    Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
    Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral inactivation vs biological activity.
    Barrowcliffe TW
    Dev Biol Stand; 1993; 81():125-35. PubMed ID: 8174795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of retroviruses in biologicals manufactured for human use.
    Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
    Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective study of the practice of "look-back" procedures, on the incidence of HIV-1/2-positive blood donors and the risk of transfusion-associated HIV infection in public-community blood banks in Germany].
    Zeiler T; Kretschmer V; Sibrowski W
    Infusionsther Transfusionsmed; 1994 Dec; 21(6):362-7. PubMed ID: 7873914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrin glue safety: inactivation of potential viral contaminants by pasteurization of the human plasma components.
    Hilfenhaus J; Weidmann E
    Arzneimittelforschung; 1985; 35(11):1617-9. PubMed ID: 3004516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transfusion-associated HIV infection].
    Gürtler LG; Eberle J; Bader L
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():7-10. PubMed ID: 8000258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.